ClinicalTrials.gg
Status unknownNCT03605511Updated Sep 25, 2018

TTP and aHUS in Complicated Pregnancies

An observational study in Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome and Pre-Eclampsia, sponsored by University College, London. Status unknown at 1 site in United Kingdom. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-09-25.

Sponsored by University College, London · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
16 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom — none open to participants now, 1 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · United Kingdom.

Started
2018
with 1 other
Observational
4 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
3 of 17
University College, London

Among the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom, this one is one of 2 that started in 2018, is one of 4 observational ones, and was the 10th registered.

Purpura, Thrombotic Thrombocytopenic

67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.

Browse Purpura, Thrombotic Thrombocytopenic studies →

Open to participants now

None of the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom is open now. The open studies under Purpura, Thrombotic Thrombocytopenic, anywhere →

Who these studies take

Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 16 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom as a file.
02

Study summary

A single site observational study aiming to:

(i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii) Characterise the clinical features of these cases and (ii) Identify clinical features or biomarkers which may help distinguish TTP/aHUS from other complications of pregnancy such as preeclampsia

03

Conditions studied

  • Thrombotic Thrombocytopenic Purpura
  • Atypical Hemolytic Uremic Syndrome
  • Pre-Eclampsia
  • HELLP Syndrome
  • Thrombocytopenia
  • IUGR
  • Stillbirth
  • Thrombotic Microangiopathies
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

All women receiving obstetric care at University College Hospitals London NHS Trust over the study period

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women, either currently pregnant or recently postpartum, and affected by one or more of the following complications in the index pregnancy: (i) Preeclampsia with evidence of end organ damage (renal/ liver/ haematological/ neurological) or uteroplacental dysfunction (FGR/IUFD) (ii) HELLP syndrome (iii) Fetal growth restriction (FGR) (growth \<10th centile) that is unexplained (ie not due to infection, fetal structural anomaly, fetal chromosomal or pre-existing maternal medical problem) (iv) Intrauterine fetal demise (IUFD) after 20 weeks' gestation that is unexplained (v) Unexplained new onset renal impairment (defined by serum creatinine >85umol/L 1st trimester, or >80umol/L 2nd trimester, or >90 umol/L 3rd trimester[32]; OR an increase in serum creatinine by (i) at least 1.5 times the baseline or (ii) of equal or greater than 26.5umol/L (as per KDIGO criteria) (vi) Unexplained new onset thrombocytopenia ( \<75x10\^9/L)

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of TTP or aHUS
  • Known disorder of complement dysregulation
  • Patients not wishing to participate
  • Patients aged less than 16
  • Patients lacking capacity to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testADAMTS 13, complement and angiogenic biomarkers

    ADAMTS 13, complement and angiogenic biomarkers

06

What researchers measure

Primary outcomes

  1. Frequency of TTP and aHUS in the cohort

    Number of new cases identified as a percentage of sample size

    Time frame: At study completion, approximately 18 months after recruitment of first patient

07

Study locations

1 of 1 sites recruiting
  • University College London Hospital
    London, NW1 2PG, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2018 (actual). Primary completion is estimated for Mar 2020, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2018
First posted
Jul 30, 2018
StartActual
Sep 21, 2018
Primary completionEst.
Mar 14, 2020
CompletionEst.
Mar 14, 2020
Last update
Sep 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03605511
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Sep 21, 2018
Primary completion
Mar 14, 2020 (estimated)
Completion
Mar 14, 2020 (estimated)
Last update
Sep 25, 2018

Study contacts

Lucy Neave, MBBS
Contact
lucy.neave.17@ucl.ac.uk
+44 203 447 9884

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion